Research Paper Volume 13, Issue 8 pp 12129—12142

Long noncoding RNA DLGAP1-AS1 promotes the progression of glioma by regulating the miR-1297/EZH2 axis

Liang Liu1, *, , Xiaojian Li1, *, , Yan Shi1, , Hua Chen2, ,

  • 1 Department of Neurosurgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
  • 2 Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
* Equal contribution

Received: October 19, 2020       Accepted: March 13, 2021       Published: April 26, 2021
How to Cite

Copyright: © 2021 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Dysregulated lncRNAs have been implicated in a plethora of tumors, including glioma. One such oncogenic lncRNAs that has been reported in several cancers is the lncRNA DLGAP1 antisense RNA 1 (DLGAP1-AS1). This study seeks to characterize the expression of DLGAP1-AS1 in glioma tissues, which we found to be raised in both glioma samples and cell lines. Functional experiments revealed that DLGAP1-AS1 promoted in vitro glioma cell invasion, migration and proliferation. DLGAP1-AS1 was found to function as a miR-1297 sponge, based on information from luciferase reporter assays, RNA pull-down assays and publicly available online databases. miR-1297 was in turn found to functionally target EZH2. DLGAP1-AS1 modulated EZH2 expressions through miR-1297 sponging. Glioma progression appears to be supported DLGAP1-AS1 -promoted activation of the miR-1297/EZH2 axis. The components of this axis may function as therapeutic targets for glioma.


GBM: Glioblastoma multiforme; lncRNAs: long noncoding RNAs; TMZ: temozolomide; DLGAP1-AS1: DLGAP1 antisense RNA 1; EZH2: zeste homologue 2; NBTs: normal brain tissues; NHAs: normal human astrocyte cell lines; ceRNAs: competing endogenous RNAs.